Senti Biosciences Secures $53 Million Series A to Build the Future of Gene and Cell-Based Therapies – Markets Insider
Markets Insider |
Senti Biosciences Secures $53 Million Series A to Build the Future of Gene and Cell-Based Therapies
Markets Insider SOUTH SAN FRANCISCO, Calif., Feb. 27, 2018 /PRNewswire/ — Senti Biosciences, the synthetic biology company developing next-generation adaptive therapies for important diseases, today announced the completion of a $53M round of funding to support them … |
